SUMMARY Lidoflazine, a calcium channel blocker, was administered to dogs following twelve minutes of cerebral ischemia, induced by aortic cross-clamping. The effects of lidoflazine (1 nig/kg i.v.) on cerebral blood flow following ischemia was studied in 15 anesthetized, mechanically ventilated dogs. Cerebral blood flow was measured with the radiolabclled microsphere technique before and 10, 30, 60, 90 and 150 minutes following ischemia. Cerebral blood flow increased in all brain regions following ischemia, but by 60 minutes had decreased to control values. Lidoflazine had no effect on this reperfusion phenomenon, or on the distribution of blood flow within the brain. Regional cerebral blood flow was also not altered by lidoflazine therapy. Our data demonstrate that this dose of lidoflazine has no effect on regional or total cerebral blood flow following 12 minutes of cerebral ischemia in dogs. These data do not support perfusion preservation as a mechanism of amelioration of neurologic injury after ischemia by this calcium channel blocker.
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CEREBRAL ISCHEMIC INJURY remains one of the most difficult problems in intensive care, and is the final common pathway of many disease entities. Therapy for cerebral ischemia such as hypothermia,' barbiturate coma, 2 " 5 hemodilution, 6 8 heparinization, 6 dextran infusion, 7 intentional hypertension, 910 and control of intracranial pressure have been used without significant improvement in mortality or morbidity of patients. Most recently, calcium (slow channel) blocking agents have been proposed to ameliorate ischemic injury. Flameng et al" demonstrated that lidoflazine protected the myocardium during bypass procedures. White and colleagues' 2 demonstrated that flunarazine, an agent similar to lidoflazine, ameliorated or reversed the increase in cerebrovascular resistance seen after total cerebral ischemic injuries. Subsequently, White et al 13 demonstrated amelioration of neurologic injury in dogs treated with lidoflazine following fibrillation (15 minutes). Jackson et al 14 reported a decrease in cerebrovascular resistance following ischemia in dogs treated (post-ischemia) with nifedipine. Allen and colleagues 15 have established that nifedipine is capable of ameliorating vasospasm following subarachnoid hemorrhage. Finally, nimodipine has been shown to decrease reperfusion impairment in cats following global ischemia, 16 improve perfusion in a focal ischemic area, 17 and improve perfusion and neurologic recovery in dogs after 10 minutes of global ischemia. 18 While the mechanisms of injury may be different in the above cited examples, it is fairly well established in these studies that calcium channel blocking agents can exert an effect on outcome following ischemic injury. However, the precise mechanism of these effects is unknown.
In this study, we measured total and regional cerebral blood flow (CBF) in dogs that had been subjected to twelve minutes total cerebral ischemia. The aim of these studies was to test the hypothesis that lidoflazine could alter the pattern of CBF following cerebral ischemia.
Methods

Preparation
Fifteen mongrel dogs of either sex (12 to 30 kg) were anesthetized with sodium pentobarbital (30 mg/ kg i.v. induction, 2-3 mg/kg/hri.v. supplemental until ischemia), paralyzed with pancuronium (0.1 mg/kg i.v.) and ventilated with a positive pressure respirator via an endotracheal tube. A catheter was placed in the femoral vein for administration of fluids and sodium bicarbonate. Catheters were placed in both femoral arteries; one was advanced into the descending aorta and used to obtain the reference withdrawal blood sample during the microsphere injection. The other was used for monitoring blood pressure and for obtaining arterial blood gas samples. A left lateral fhoracotomy was performed, and the pericardium was opened. The aortic root was dissected from the pulmonary artery and an umbilical tape was placed around the aorta. An umbilical tape was also placed around the inferior vena cava. A catheter was placed directly into the left atrial appendage and was used for microsphere injection.
Measurements
Regional CBF was measured with radiolabelled microspheres (15 ± 3 micron diameter). 19 The microspheres were vigorously shaken and agitated in an ultrasonic mixer for 20 Ru or "Sr, 95 Nb, ^Sc) (3M and New England Nuclear) and the order of injection was randomized. The microspheres were injected into the left atrium over 30 seconds followed by a 10 ml saline flush. The reference blood sample was collected using a Harvard withdrawal syringe pump. The withdrawal pump was calibrated for each experiment and the reference sample was collected at a set rate of 4.94 ml/min for 5 minutes. This procedure did not alter arterial blood pressure or heart rate.
After killing the animal with KC1, the brain was Gd, "Cr, 141 Ce, " 3 Sn, ""Ru, 85 Sr, 93 Nb, and •"'Sc isotopes were 36-72, 70-174, 130-170, 280-364, 370-440, 460-550, 480-550, 710-820, and 820-1200 KeV, respectively. Six spheres were used in any given experiment. The overlap of activity of each isotope into other windows was measured, and corrected counts for each isotope (C,) were obtained by solving simultaneous equations. Blood flow was calculated as Q, = C, x Q r /C r , where 0 r is the reference sample withdrawal rate, C r is the reference sample count, C, is the tissue sample count, and Q, is the tissue blood flow. Flows were then normalized to 100 g of tissue weight.
Arterial blood pressure was continuously monitored with a Statham pressure transducer referenced to the level of the right atrium. Arterial pO 2 , pCO 2 , and pH were measured with Radiometer BMS 3 electrodes and analyzer. Oxygen saturation and hemoglobin concentration were measured using an Instrumentation Laboratory co-oximeter (Model 282). All blood samples were analyzed immediately afier drawing the samples.
Experimental Protocol
At least 30 minutes following the last supplemental dose of pentobarbital, control regional CBF was measured. The inferior vena cava was occluded, and after the blood pressure dropped to 20-40 mm Hg (within 10-15 seconds) the aortic root was occluded distal to the coronary arteries. After 12 minutes, the aortic occlusion was released, followed by release of the inferior vena cava occlusion. Sodium bicarbonate (3 meq/kg i.v.) was administered, as well as fluid volume (Ringer's lactate) to keep the mean blood pressure above 80 mm Hg. The average required volume was 750 ml. The ventilator rate was increased immediately after release of aortic occlusion, and subsequently was titrated to maintain arterial carbon dioxide tension (PaCO 2 ) between 30 and 40 torr. Subsequent CBF measurements were obtained 10, 30, 60, 90 and 150 minutes after relief of the aortic occlusion.
In seven animals, lidoflazine (1 mg/kg) (Janssen Pharmaceutica) was infused into the central venous catheter. The infusion began 2 minutes after release of aortic occlusion, and was administered via pump syringe over 3 minutes. All infusions were completed within 5 minutes after release of aortic occlusion. Infusion at this rate had no effect on arterial blood pressure.
The CBF time course and regional CBF distribution were compared between the control group (n = 8) and the lidoflazine treated group (n = 7) with two way analysis of variance. 20 Comparison of flows at each time point with control values were made with Dunnett's test for multiple comparisons. 20 In all tests, 0.05 level of significance was required. Table 1 shows the arterial blood gases and blood pressure over the time course of these experiments. Efforts were made to normalize all parameters as quickly as possible. There were no significant differ- ences in any parameters between the control and lidoflazine treated animals except arterial oxygen content. Oxygen content was elevated in lidoflazine treated animals (p < 0.001), but this was due to differences in supplemental oxygen. More importantly, however, PaCO 2 values did not differ significantly between the control group and treated group.
Results
Total CBF increased immediately after release but quickly fell toward control values ( fig. 1) . By 30 minutes after ischemia, CBF was not significantly different from the control value. Cerebrovascular resistance was decreased immediately after ischemia, and returned to the control value by 30 minutes ( fig. 2) . Lidoflazine had no effect on either the flow pattern ( fig. 1 ), or the resistance changes ( fig. 2) .
The proportion of total CBF delivered to the brainstem, cerebellum, and cerebral hemispheres was calculated from the absolute flows (tables 2 and 3). These proportions did not differ significantly during the time course of the experiments, nor were there any differences between control and treated groups.
Regional CBF increased in all brain areas following ischemia (table 2) , and fell to control values in nearly all regions by 60-150 minutes. Animals treated with lidoflazine had similar flow patterns (table 3), except that cortical flow dropped below control values at 90 and 150 minutes (p < 0.05). There were no other significant differences between the two groups for any region of the brain.
Discussion
We have confirmed the occurrence of post-ischemic cerebral hyperemia, followed by decreased cerebral perfusion. Our results show that lidoflazine had no effect on this CBF pattern after total cerebral ischemia. Cerebrovascular resistance and flow distribution were also not affected by this drug.
Lidoflazine has been shown to protect the myocardium during 60 minutes of normothermic arrest in a cardiac bypass model." In that study, ultrastructural information suggested a marked reduction of mitochondrial calcium deposition, and the authors hypothesized that lidoflazine may have prevented mitochondrial breakage and irreversible injury. Neither coronary blood flow distribution, nor cardiac oxygen consumption were evaluated in this model; however, perfusion defects probably play little role in this model. Their results suggest that lidoflazine is capable of preventing an intracellular cytotoxic event (mitochondrial breakage secondary to calcium deposition) unrelated to tissue perfusion.
White et al 12 used a thermal method to study CBF following 20 minutes global cerebral ischemia in dogs. They demonstrated that flunarazine prevented the decreased perfusion seen after ischemia. Cerebrovascular resistance was favorably altered in the treated animals. In subsequent work, 13 this group used lidoflazine and demonstrated improved neurologic outcome in treated animals following 15 minutes of ventricular fibrillation. However, they did not measure CBF in these animals, and did not delineate the mechanism of the beneficial effect of lidoflazine in their model. The lack of effect of lidoflazine on post-ischemic perfusion shown in our data is similar to those results with nifedipine. 14 Jackson et al 14 showed similar impaired reperfusion in control and nifedipine treated dogs following 11 minutes total cerebral ischemia. The cerebrovascular resistance was lower in treated animals, however, suggesting that nifedipine might reduce cerebral vasospasm" and improve perfusion. If blood pressure had been maintained after drug therapy, CBF probably would have been higher in treated animals. 14 The effects of nimodipine on CBF have been studied in normal primates, 21 primates subjected to middle cerebral artery occlusion, 17 cats subjected to 7 minutes total cerebral ischemia, 16 and dogs subjected to 10 minutes global ischemia. 18 In all these studies, which involved pretreatment with nimodipine, nimodipine increased CBF and lowered cerebrovascular resistance. In focal ischemic areas, regional flow was improved. 17 Finally, reperfusion was markedly improved after global ischemia. 16 -" I n the dog study, the authors evaluated cerebral O 2 consumption (CMRO 2 ), cerebral oxygen extraction, and neurological outcome. They concluded that nimodipine improved CBF, and that this resulted in better oxygen delivery and neurologic improvement.
Multiple calcium pathways exist, and we suggest that the discrepancy between our results and the results with other calcium channel blockers reflects a different site of action by lidoflazine administered after ischemia. Extracellular calcium influx occurs via receptoroperated channels (ROC) and via membrane depolarization sensitive channels. 16 Nimodipine does not prevent depolarization 16 -2 ' since extracellular potassium increases with ischemia even in the presence of the drug. However, vasoconstriction is prevented in vitro,' 6 and flow is improved in vivo' 6 -2 ' despite the potassium efflux. Nifedipine and nimodipine block serotonin-induced vasoconstriction in basilar arteries, 13 l6 suggesting ROC block in basilar arteries. However, nimodipine fails to block ROC flux in rabbit saphenous artery strips. 16 Thus, the drugs exert variable effects on ROC and potential sensitive channels, and these channels vary in different vascular beds. Beyond the large arterial level, the precise types and distribution of calcium channels in the cerebral vasculature are unknown. In addition, different lipid solubilities of various calcium channel blockers might cause differences in brain uptake of the drugs; it has been suggested that the more lipid soluble nifedipine might have better access to cerebral vessels. 13 Data about brain uptake of lidoflazine are unavailable.
In addition to plasmalemmal channels (ROC, potential sensitive channels, slow leak channels), intracellular calcium flux normally occurs, and cytosolic cal- 22 ATP stores are rapidly depleted, and Na-K ATPase activity drops, with subsequent cellular edema. Massive mitochondrial calcium deposition results in cristal breakage and the cellular injury becomes irreversible. Lidoflazine prevents mitochondrial calcium deposition." Pretreatment with calcium blockers could prevent mitochondrial calcium deposition indirectly by preventing the increased cytosolic calcium activity (via potential sensitive channel block) associated with ischemia. Such a mechanism fails to explain the amelioration of damage seen by White, who administered lidoflazine after the ischemic insult. 13 Extracellular calcium influx would have already occurred, both during prolonged ischemia (15 minutes) and in the immediate post release period (5 minutes). With this massive calcium influx, vascular smooth muscle tone would appear similar in treated and untreated animals. In this study we have only measured cerebral blood flow, and have not examined calcium flux. However, plasmalemmal block seems an unlikely mechanism since Harris et al failed to show an effect of nimodipine upon extracellular calcium or potassium activities after middle cerebral artery occlusion. 17 It is possible that amelioration of damage could occur from blocking intracellular calcium flux, specifically by blocking mitochondrial calcium deposition. Such a mechanism of action by lidoflazine would be independent of CBF pattern, which is consistent with our results.
In summary, we have shown that lidoflazine, administered after 12 minutes of total cerebral ischemia, had no effect on total or regional CBF, distribution of CBF, or cerebrovascular resistance. We suggest that the ameliorative effects of this drug, as demonstrated by White's group,' 3 must be due to effects on cytotoxic intracellular events rather than perfusion preservation. We suggest that pretreatment experiments deal with an entirely different situation, and might permit calcium blockers to exert a different mechanism of action on the ischemic model (i.e. plasmalemmal channel block). Further studies with these agents should use post-ischemic treatment schedules prior to acceptance of their efficacy in cerebral ischemic injury.
